David Watson is the ABPI’s Director of Pricing and the PPRS. His primary focus is the 2014 Pharmaceutical Price Regulation Scheme (PPRS) which is the main UK deal between industry and government on medicines policy. The scheme is now into its fourth year, and has involved the industry underwriting most of the growth in branded medicines covered by the agreement, as well as a variety of commitments on access and uptake. Previously David worked in consulting, focusing on global projects within the Pharma industry on brand marketing, launch planning and biosimilars. David spent much of his career with Pfizer, where he held a variety of UK and European roles across the business. He led work in European markets to establish new sales channels including the Direct to Pharmacy (DTP) initiative.